Skip to main content

Advertisement

SpringerLink
Log in

Clinical Pathways of Third-Line Treatment of Overactive Bladder in the Elderly

  • Geriatric Bladder Dysfunction (GM Ghoniem, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) is a syndrome of urinary urgency, usually accompanied by frequency, nocturia, and sometimes urinary urgency incontinence. There are many guidelines for the OAB treatment which are constructed on a stepwise fashion starting from the least invasive to the more invasive therapy. The emergence of third-line therapy (AUA/SUFU guidelines) has resulted in significant decrease of more invasive surgery and improved patients’ quality of life. The aim of a clinical pathway is to improve the quality of care, reduce risks, increase patient satisfaction, and increase the efficiency in the use of resources. The available options for the third-line OAB treatments include intravesical injection of botulinum toxin A, percutaneous tibial nerve stimulation (PTNS), and sacral nerve stimulation (SNS). The available evidence confirms that all three treatment approaches are well tolerated and effective, although only botulinum toxin type A (BoNTA) and SNS can achieve nearly a cure of urgency urinary incontinence (UUI). The choice among the different third-line treatment depends on patient preference, availability, and local expertise. The application of these pathways can improve incontinence care by letting physicians adequately communicate with patients and select individualized therapy at an early stage especially for elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Haylen BT et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.

    PubMed  Google Scholar 

  2. Haab F. Chapter 1: the conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn. 2014;33 Suppl 3:S2–5.

    Article  PubMed  Google Scholar 

  3. Schurch B, Carda S. OnabotulinumtoxinA and multiple sclerosis. Ann Phys Rehabil Med. 2014;57(5):302–14.

    Article  CAS  PubMed  Google Scholar 

  4. Malde S et al. Patient experience and satisfaction with onabotulinumtoxin A for refractory overactive bladder. BJU Int. 2015;116(3):443–9.

    Article  CAS  PubMed  Google Scholar 

  5. Bauer SB. Neurogenic bladder: etiology and assessment. Pediatr Nephrol. 2008;23(4):541–51.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Stewart WF et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

    CAS  PubMed  Google Scholar 

  7. Sicras-Mainar A et al. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain. BMC Urol. 2013;13:51.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Shah D, Badlani G. Treatment of overactive bladder and incontinence in the elderly. Rev Urol. 2002;4 Suppl 4:S38–43.

    PubMed Central  PubMed  Google Scholar 

  9. Novara G et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol. 2010;58(2):218–38.

    Article  PubMed  Google Scholar 

  10. Gormley EA et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. This is good article which considered as updated amendmnet guidelines for the diagnosis and treatment of OAB in AUA/SUFU.

  11. Nambiar A, Lucas M. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). Neurourol Urodyn. 2014;33 Suppl 3:S21–5.

    Article  PubMed  Google Scholar 

  12. Hermieu JF et al. Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management: translation of French recommendations. Prog Urol. 2014;24(11):e1–7.

    Article  PubMed  Google Scholar 

  13. Sicras-Mainar A et al. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J. 2014;25(4):485–92.

    Article  PubMed  Google Scholar 

  14. Elwyn G et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–7. This is the main point in the treatment of any disease in general and OAB in specific.  The decision to share with the patient and address “what matters most”, is the main key in the choice of treatment.

  15. Kelleher CJ et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997;104(9):988–93.

    Article  CAS  PubMed  Google Scholar 

  16. Schabert VF et al. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15(4 Suppl):S118–22.

    PubMed  Google Scholar 

  17. Jundt K et al. Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet. 2011;284(3):663–6.

    Article  CAS  PubMed  Google Scholar 

  18. Marinkovic SP et al. The management of overactive bladder syndrome. BMJ. 2012;344:e2365.

    Article  PubMed  Google Scholar 

  19. Anger JT et al. Women’s experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups. Neurourol Urodyn. 2011;30(7):1295–9.

    PubMed Central  PubMed  Google Scholar 

  20. Amarenco G, Deffieux X. How to define refractory overactive bladder? Prog Urol. 2014;24(4):213–4.

    Article  CAS  PubMed  Google Scholar 

  21. Nitti VW et al. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion. Neurourol Urodyn. 2010;29(4):652–7.

    Article  PubMed  Google Scholar 

  22. Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology. 2006;68(2 Suppl):29–37.

    Article  PubMed  Google Scholar 

  23. Schwantes U, Grosse J, Wiedemann A. Refractory overactive bladder: a common problem? Int Urogynecol J. 2015.

  24. Appell RA et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76(4):358–63.

    Article  CAS  PubMed  Google Scholar 

  25. Van Kerrebroeck P et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414–21.

    Article  PubMed  Google Scholar 

  26. Knuepfer S, Juenemann KP. Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol. 2014;6(1):34–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Dolly JO, Lawrence GW. Chapter 3: molecular basis for the therapeutic effectiveness of botulinum neurotoxin type a. Neurourol Urodyn. 2014;33 Suppl 3:S14–20.

    Article  CAS  PubMed  Google Scholar 

  28. Cruz F, Nitti V. Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourol Urodyn. 2014;33 Suppl 3:S26–31.

    Article  PubMed  Google Scholar 

  29. Tincello DG, Rashid T, Revicky V. Emerging treatments for overactive bladder: clinical potential of botulinum toxins. Res Rep Urol. 2014;6:51–7. This reviews good safety, durability, and cost for Botox in OAB.

  30. Chapple C et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.

    Article  CAS  PubMed  Google Scholar 

  31. Mohee A et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106–13.

    Article  CAS  PubMed  Google Scholar 

  32. Fowler CJ et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57.

    Article  CAS  PubMed  Google Scholar 

  33. Chughtai B et al. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol. 2014;21(2):7217–21.

    PubMed  Google Scholar 

  34. Chancellor MB et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon. 2013;67:129–40.

    Article  CAS  PubMed  Google Scholar 

  35. National Collaborating Centre for Women’s. and Children’s Health. National Institute for Health and Clinical Excellence: guidance, in urinary incontinence in women: the management of urinary incontinence in women. London: Royal College of Obstetricians and Gynaecologists (UK) Copyright (c) 2013 National Collaborating Centre for Women's and Children's Health; 2013.

    Google Scholar 

  36. Hamid R et al. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX((R))) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective. Pharmacoeconomics. 2015;33(4):381–93.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Anger JT et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol. 2010;183(6):2258–64.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Nitti VW et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.

    Article  CAS  PubMed  Google Scholar 

  39. Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189(5):1804–10.

    Article  CAS  PubMed  Google Scholar 

  40. Schurch B et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol. 2000;164(3 Pt 1):692–7.

    Article  CAS  PubMed  Google Scholar 

  41. Harper M et al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int. 2003;92(3):325–6.

    Article  CAS  PubMed  Google Scholar 

  42. Cohen BL et al. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol. 2007;177(3):1006–10. discussion 1010.

    Article  PubMed  Google Scholar 

  43. Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005;19(7):880–2.

    Article  PubMed  Google Scholar 

  44. Cameron AP et al. National trends in the usage and success of sacral nerve test stimulation. J Urol. 2011;185(3):970–5.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn. 2008;27(1):28–33.

    Article  PubMed  Google Scholar 

  46. Primus G, Kramer G. Maximal external electrical stimulation for treatment of neurogenic or non-neurogenic urgency and/or urge incontinence. Neurourol Urodyn. 1996;15(3):187–94.

    Article  CAS  PubMed  Google Scholar 

  47. Kessler TM et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865–74.

    Article  PubMed  Google Scholar 

  48. Lay AH, Das AK. The role of neuromodulation in patients with neurogenic overactive bladder. Curr Urol Rep. 2012;13(5):343–7.

    Article  PubMed  Google Scholar 

  49. Ohlsson BL. Effects of some different pulse parameters on the perception of intravaginal and intra-anal electrical stimulation. Med Biol Eng Comput. 1988;26(5):503–8.

    Article  CAS  PubMed  Google Scholar 

  50. Laudano MA et al. Disparities in the use of sacral neuromodulation among Medicare beneficiaries. J Urol. 2015;194(2):449–53.

    Article  PubMed  Google Scholar 

  51. Reynolds WS, Bales GT. Re: Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. P. E. van Kerrebroeck, A. C. van Voskuilen, J. P. Heesakkers, A. A. Lycklama a Nijholt, S. Siegel, U. Jonas, C. J. Fowler, M. Fall, J. B. Gajewski, M. M. Hassouna, F. Cappellano, M. M. Elhilali, D. F. Milam, A. K. Das, H. E. Dijkema and U. van den Hombergh. J Urol 2007; 178: 2029-2034. J Urol. 2008;179(6):2483–4. author reply 2484.

    Article  PubMed  Google Scholar 

  52. Janknegt RA, Weil EH, Eerdmans PH. Improving neuromodulation technique for refractory voiding dysfunctions: two-stage implant. Urology. 1997;49(3):358–62.

    Article  CAS  PubMed  Google Scholar 

  53. Spinelli M et al. New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol. 2003;170(5):1905–7.

    Article  PubMed  Google Scholar 

  54. Kessler TM et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2007;51(5):1357–63.

    Article  PubMed  Google Scholar 

  55. Al-Shaiji TF, Banakhar M, Hassouna MM. Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms. Adv Urol. 2011;2011:757454. This paper provides a review on the indications, possible mechanisms of action, surgical aspects and possible complications, and safety issues of the SNM & PTNS. The efficacy of the technique is also addressed.

  56. Nuhoglu B et al. Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(3):204–7.

    Article  PubMed  Google Scholar 

  57. Bemelmans BL, Mundy AR, Craggs MD. Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. Eur Urol. 1999;36(2):81–91.

    Article  CAS  PubMed  Google Scholar 

  58. Nakamura M et al. Bladder inhibition by electrical stimulation of the perianal skin. Urol Int. 1986;41(1):62–3.

    Article  CAS  PubMed  Google Scholar 

  59. Klingler HC et al. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology. 2000;56(5):766–71.

    Article  CAS  PubMed  Google Scholar 

  60. MacDiarmid SA et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183(1):234–40.

    Article  PubMed  Google Scholar 

  61. Peters KM et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43.

    Article  PubMed  Google Scholar 

  62. Karademir K et al. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. Scand J Urol Nephrol. 2005;39(3):230–3.

    Article  PubMed  Google Scholar 

  63. Gaziev G et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013;13:61. Good systemic review: four RCT for OAB which showed Level 1 evidence of efficacy for PTNS.

  64. Peters KM et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61.

    Article  CAS  PubMed  Google Scholar 

  65. Peters KM et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–201.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Urology, University of California, Irvine, 333 City Blvd. West, Ste 2100, Orange, CA, 92868, USA

    Bilal Farhan & Gamal Ghoniem

Authors
  1. Bilal Farhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gamal Ghoniem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gamal Ghoniem.

Additional information

This article is part of the Topical Collection on Geriatric Bladder Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Farhan, B., Ghoniem, G. Clinical Pathways of Third-Line Treatment of Overactive Bladder in the Elderly. Curr Bladder Dysfunct Rep 10, 381–390 (2015). https://doi.org/10.1007/s11884-015-0341-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-015-0341-4

Keywords

Search

Navigation